Raymond A Kevin, Jaffe Norman
Department of Pathology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009, USA.
Cancer Treat Res. 2009;152:63-84. doi: 10.1007/978-1-4419-0284-9_4.
Osteosarcoma is a primary malignant tumor of the bone in which proliferating neoplastic cells produce osteoid and/or bone, if only in small amounts. This histological principle defines a tumor that usually affects young males more frequently than females, and disproportionately involves the long bones of the appendicular skeleton. These tumors are generally locally aggressive and tend to produce early, lethal systemic metastases. However, osteosarcoma is not a single disease but a family of neoplasms, sharing the single histological finding of osseous matrix production in association with malignant cells. The majority (i.e., 75%) of cases are relatively stereotypical from the demographic, clinical, radiographic and histologic points of view. These tumors generally occur in the metaphyseal portion of the medullary cavity of the long bone and are referred to as "Conventional Osteosarcoma." The group is sub classified by the form of the dominant matrix present within the tumor, which may be bone, cartilage or fibrous tissue, and it is correspondingly referred to as osteoblastic, chondroblastic and fibroblastic osteosarcoma. The remaining 25% of cases have unique parameters that allow reproducible identification of tumors which are biologically different from conventional osteosarcoma and are referred to as "Variants." The parameters identifying Variants fall into one of three major groups: (1) clinical factors, (2) histologic findings and (3) location of origin--within or on the cortex. Because of their inherent biological difference from Conventional Osteosarcoma, the Variants identify cases which must be excluded from analysis of data pertaining to the treatment of the majority of cases: Conventional Osteosarcoma. The diagnostic parameters of osteosarcoma must be sufficiently inclusive to identify all the members of this potentially lethal tumor. Conversely, criteria for sub classification must be restricted to assure homogenous populations of tumors productively incorporating different biological behavior and the potential for development of unique treatment strategies which are different from those for Conventional Osteosarcoma. This can be designated "Classification Based Therapy" or "Therapy Based Osteosarcoma." With this background, we will discuss the highly disciplined approach to the management of osteosarcoma from the pathologist's perspective. Factors governing the assessment of the response to preoperative chemotherapy will also be reviewed.
骨肉瘤是一种原发性骨恶性肿瘤,其中增殖的肿瘤细胞会产生类骨质和/或骨组织,即便数量很少。这一组织学特征定义了一种肿瘤,通常男性比女性更易受其影响,且不成比例地累及四肢骨骼的长骨。这些肿瘤一般具有局部侵袭性,且往往早期就会发生致命的全身转移。然而,骨肉瘤并非单一疾病,而是一类肿瘤,其共同的单一组织学特征是与恶性细胞相关的骨基质生成。从人口统计学、临床、影像学和组织学角度来看,大多数(即75%)病例相对具有典型性。这些肿瘤通常发生在长骨髓腔的干骺端部分,被称为“传统骨肉瘤”。该类别根据肿瘤内主要基质的形式进行细分,基质可以是骨、软骨或纤维组织,相应地被称为成骨细胞型、软骨细胞型和成纤维细胞型骨肉瘤。其余25%的病例具有独特参数,可重复性地识别出与传统骨肉瘤生物学特性不同的肿瘤,这些肿瘤被称为“变异型”。识别变异型的参数可分为三大类之一:(1)临床因素,(2)组织学发现,(3)起源位置——在皮质内或皮质上。由于其与传统骨肉瘤存在固有的生物学差异,变异型确定了在分析大多数病例(传统骨肉瘤)的治疗数据时必须排除的病例。骨肉瘤的诊断参数必须足够全面以识别这种潜在致命肿瘤的所有成员。相反,细分标准必须严格,以确保肿瘤群体同质化,有效地纳入不同的生物学行为以及制定不同于传统骨肉瘤的独特治疗策略的可能性。这可被称为“基于分类的治疗”或“基于骨肉瘤的治疗”。在此背景下,我们将从病理学家的角度讨论骨肉瘤管理的严格方法。还将回顾影响术前化疗反应评估的因素。